2021 NEJM) showed 14.9% weight loss at 68 weeks on semaglutide
Bi-weekly Dosing Regimen Significantly Enhances Patient Compliance Currently, as the world's first bi-weekly GLP-1RA to enter Phase III clinical research, Bofanglutide has advanced into the critical Phase III stage of its global development for three proposed indications: obesity/overweight, type 2 diabetes mellitus (T2DM), and obstructive sleep apnea (OSA)
Dysautonomia and POTS: The active Vitamin B6 (P-5-P) in the formula is required to synthesize GABA, an inhibitory neurotransmitter that helps calm the overactive sympathetic nervous system, potentially easing the rapid heart rate and adrenaline surges associated with dysautonomia
Richardson recommends eating food sources of probiotics like yogurt, sauerkraut, tempeh, and kimchi. Fiber Fiber is finally getting its flowers
Most symptoms are most pronounced during dose escalation phases and tend to diminish within 4-8 weeks of maintaining a stable dose
Biomark Insights 10:103112